ArgoBio
8 rue Francois Villon, Paris, Île-de-France, 75015, France
Overview
Argobio is a start-up studio devoted to developing unique therapeutic solutions, with the purpose of nurturing and launching revolutionary biotech firms. It sources cutting-edge early-stage projects from leading European academic research institutes in order to cultivate and nurture these projects before launching companies. The main focus is on rare diseases, neurological issues, oncology, and immunology. Additionally, the studio is looking to create promising platform technologies for therapeutic products.
- Total investments
- 3
- Lead investments
- 0
- Investments · 12mo
- 3
- Active investors
- 3
Sector focus
- Biotechnology
Investment portfolio
- Laigo Bio
Participated · Seed · Mar 2026
Laigo Bio is developing the SureTACs platform to generate bispecific antibodies that selectively degrade disease-causing membrane proteins by pairing an E3 ligase with a target protein to trigger ubiquitination and lysosomal degradation. The approach is intended to enable highly selective elimination of disease-driving membrane targets and to produce first-in-class, dual-targeted therapies. Laigo is focusing its programs on oncology as well as autoimmune and immunology indications, including graft rejection, and is advancing multiple candidate programs. The company reports in vivo and in vitro efficacy with a claimed high degree of selectivity and improved toxicity and safety. Laigo is advancing its oncology pipeline toward clinical development and progressing three autoimmune/immunology programs with support from its recent seed financing.
- Enodia Therapeutics
Participated · Seed · Jan 2026
Enodia Therapeutics is building a small-molecule drug discovery platform that selectively modulates the SEC61 translocon, enabling degradation of secreted and membrane proteins before they leave the endoplasmic reticulum. The approach blends a tailored library of signal-peptide cell lines, proteomics-based secretome analysis and machine-learning models to achieve unprecedented selectivity in targeted protein degradation. Originating from research at the Institut Pasteur and incubated by Argobio Studio, the company is initially pursuing inflammatory and autoimmune disease programs while exploring applications in oncology and viral infections. Management intends to advance the lead program to preclinical candidate selection within the next twelve months, marking a key value inflection point. The platform leverages several families of well-characterized inhibitors, offering the potential to unlock previously undruggable targets. Enodia’s strategy emphasizes repeated translation of complex SEC61 biology into differentiated drug candidates and broad partnering potential. The recent seed financing provides the capital to validate the platform and expand the early pipeline. No commercial revenue or clinical-stage assets have been disclosed to date.